Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Co. (NYSE:LLY) has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.
禮來（紐交所: LLY）已任命盧卡斯·蒙塔塞爲執行副總裁兼首席財務官，即日起生效。
What Happened: Montarce, who joined Lilly in 2001, has held numerous finance leadership positions. His roles included group vice president, corporate controller, and CFO of Lilly Research Laboratories; vice president, finance and CFO of Lilly International; and vice president, finance, and global CFO of Elanco Health.
Montarce於2001年加入了禮來，並擔任過多個財務領導職位。他的職務包括集團副總裁、公司控制器和禮來研究實驗室的首席財務官；國際部的財務副總裁和首席財務官；以及Elanco Health的財務副總裁和全球首席財務官。
Most recently, Montarce served as Lilly's president and general manager for the Spain, Portugal, and Greece hub. He holds a bachelor's degree in business accounting from Catholic University (Argentina) and a master's degree in business administration from the Center for Macroeconomic Studies of Argentina.
最近，蒙塔塞擔任了禮來西班牙、葡萄牙和希臘地區的總經理。他擁有阿根廷天主教大學的工商會計學士學位，以及阿根廷宏觀經濟研究中心的工商管理碩士學位。
David Ricks, chair and CEO stated, "We are excited to announce Lucas as Lilly's next CFO, following a competitive search across health care, tech, and general industries."
董事長兼CEO大衛·瑞克斯表示：「我們很高興宣佈盧卡斯將成爲禮來的下任首席財務官，經過醫療保健、科技和一般行業的競爭性搜索後。」
Montarce expressed his commitment to building on Lilly's strong financial foundation and driving continued success. "I am honored to step into this role during such a significant time in our company's history," he said.
蒙塔塞表示他致力於發展禮來強大的財務基礎，推動持續成功。「在我們公司歷史上這樣重要的時刻接任這一職務，我感到非常榮幸，」他說。
Why It Matters: The appointment of Montarce as CFO comes at a pivotal time for Eli Lilly. The company has been in the spotlight for its advancements in the weight loss and GLP-1 space. Roundhill Investments CEO Dave Mazza recently likened Eli Lilly to NVIDIA Corp (NASDAQ:NVDA) in terms of market leadership and growth potential.
爲什麼重要：任命蒙塔塞爲首席財務官正值禮來關鍵時刻。該公司因在減肥和GLP-1領域的進展而備受關注。Roundhill Investments首席執行官戴夫·馬紮最近將禮來與NVIDIA Corp（納斯達克: NVDA）相提並論，稱其在市場領導地位和增長潛力方面類似。
Additionally, Eli Lilly's Alzheimer's drug, donanemab, is facing potential rejection by the U.K.'s National Health Service (NHS) due to cost and safety concerns, following a similar decision on Biogen Inc's (NASDAQ:BIIB) Leqembi. This has added pressure on the company to navigate regulatory challenges effectively.
此外，禮來的阿爾茨海默病藥物多那�美正面臨着英國國家醫療服務體系（NHS）可能因成本和安全問題而拒絕的風險，此前類似決定也發生在Biogen Inc（納斯達克: BIIB）的Leqembi上。這給該公司增加了有效應對監管挑戰的壓力。
Montarce's appointment also follows the resignation of former CFO Anat Ashkenazi, who left to pursue a new career. Gordon Brooks has been serving as interim CFO since Jul. 15.
蒙塔塞的任命還是在前首席財務官阿納特·阿什克納茲辭職後進行的，她離職去追求新的職業道路。戈登·布魯克斯自7月15日起一直擔任臨時CFO。
Moreover, Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. This move is part of a broader strategy to maintain its market position amid ongoing FDA debates about drug shortages.
此外，禮來正在加大力度打擊其知名的壓抑食慾藥物Mounjaro和Zepbound的仿製品。這一舉措是爲了在持續進行FDA關於藥物短缺的討論的背景下保持其市場地位的更廣泛策略的一部分。
Price Action: Eli Lilly and Co closed at $908.27 on Monday, gaining 0.62% for the day. In after-hours trading, the stock dipped 0.027%. Year to date, Eli Lilly's stock has surged 53.37%, according to data from Benzing Pro.
股價走勢：禮來週一收盤價爲908.27美元，當日上漲0.62%。盤後交易中，股價下跌0.027%。據Benzing Pro的數據，截至目前，禮來的股價已經上漲了53.37%。
